F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

The Food and Drug Administration approved daraxonrasib for pancreatic cancer treatment. In a clinical trial, patients receiving the pill lived a median of twice as long as those receiving chemotherapy.

Next story